Anti-asthmatic agents: Difference between revisions

Content deleted Content added
Commenting on submission (AFCH)
Line 1:
{{AFC submission|||u=G.J.ThomThom|ns=2|ts=20240529133622}} <!-- Do not remove this line! -->
 
{{AFC comment|1=Notable and well referenced, thank you [[User:Ozzie10aaaa|Ozzie10aaaa]] ([[User talk:Ozzie10aaaa|talk]]) 14:46, 18 July 2024 (UTC)}}
 
----
 
{{Draft topics|chemistry|medicine-and-health}}
{{AfC topic|stem}}
 
{{AfC submission|||ts=20240529133622|u=G.J.ThomThom|ns=2}}
'''Anti-asthmatic agents''' refer to drugs that can aid in airway smooth muscle dilation to allow normal breathing during an [[asthma attack]] or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies and related hospital visits.
 
Line 132 ⟶ 138:
===== Reliever: As-needed-only low dose ICS-formoterol =====
The rationale behind using inhaled corticosteroids and formoterol combination therapy as a reliever as opposed to salbutamol, a short-acting β2-adrenergic agonist, is that this dosage regimen shows a reduction in the severe asthma exacerbation risk compared with using β2-adrenergic agonists reliever. As inhaled formoterol medications are often accompanied by a corticosteroid, this combination is a simpler regimen for patients as it utilizes the same formulation for both reliever and maintenance therapy as well as providing a long duration of bronchodilation effect.<ref name=":0" />
 
== References ==